Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HTDS running .03-.032 insiders? court case today
HTDS Running, insiders?
.030-.032
SPWP SPWP
SUPERWIPES INC Other OTC
Notices of Proposed Sale Reported on Form 144 Description / Hide Summary
Last 3 Mo. Last 12 Mo.
Number of Filings 1 1
Total Proposed Sales (Shares) 2,500,000 2,500,000
Click on the column header links to resort ascending or descending .
Filer
Select a filer below for more information. Relation File Date Shares Broker
QUENNEVILLE, MARIO CEO 11/30/2004 2,500,000
C G F SECURITIES LLC
http://www.nasdaq.com/asp/holdings.asp?mode=&kind=&symbol=HTDS&symbol=SPWP&symbol=&a...
.026 at 11.43am lets gooooooooo
Great post, thanks:
By: dbaileyway7
30 Dec 2004, 09:48 AM EST
Msg. 854 of 863
Jump to msg. #
Email to Mario this morning! This is his response.
From: Dbaileyway7Sent: Thursday, December 30, 2004 7:18 AM
To: Mario@knology.net
Subject: Superwipes
Mario, I have E-mailed you several times in the past as a shareholder. Today, I contact you to say I think you and your employees are doing a great job. I feel it is just a matter of time for you and Superwipes. I will be adding to my position as time goes on.
Do you have any idea how many shares "Walter" has left? I would think that it just eats at him to know you are moving Superwipes forward, and very well I might add.
In closing, I wish for Superwipes to become a fully reporting company in the near future, to get away from this Pink Sheet soap opera.
Good Luck MARIO, and have a great new year!
-------------------------------------------------------------------------------------------------------------------------
I have 34 court cases with Walter, I have seized many shares from him and his group. I hope the court will rule on our side. The shares seized have4 been sold short.
Happy Holidays,
mario
SUPERWIPES float in Mardi Gras.
.023, lets break
TAKI, whats up, I cant fill a 100K order.
Give me some level II info.
When I was a child, I spoke as a child, I understood as a child, I thought as a child; but when I became a man, I put away childish things.
Corinthians 13:11
Merry Christmas my Brothers and Sisters.
When I was a child, I spoke as a child, I understood as a child, I thought as a child; but when I became a man, I put away childish things.
Corinthians 13:11
Merry Christmas my Brothers and Sisters.
ATKJ - trading suspended <<<
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
SECURITIES EXCHANGE ACT OF 1934
RELEASE NO. 50923 / December 23, 2004
The Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the “Exchange Act”), of trading of the securities of ArTec, Inc. (“ATKJ”) a Nevada corporation, at 9:30 a.m. EST on December 23, 2004, and terminating at 11:59 p.m. EST on January 7, 2005.
The Commission temporarily suspended trading in the securities of ATKJ because it appears to the Commission that there is a lack of current and accurate information concerning the securities of ATKJ because of questions regarding the accuracy of assertions by ATKJ and others, on ATKJ’s website, in ATKJ’s press releases, and in public statements to investors concerning, among other things, testing of ATKJ’s Tubercin substance for use in treating cancer patients.
The best post:
By: pauld
23 Dec 2004, 07:39 AM EST
Msg. 742 of 742
Jump to msg. #
Reasons to buy and hold
A) This is a real brick and mortar company
B) It has many real products past development stage.
C) All of its products work exceptionally well, smell better and are safer to use than the competitors.
D) The company has one of its products in over 750 retail locations under the Barielle name.
E) The company has recently been introduced into the Duane Reade chain of 250 stores with an initail order in excess of $100,000.
F) The company is reported to have turned down investment capital without bothering to look at the terms.
G) Over 60 other chain stores have designated Superwipe Inc as a vendor.
H) The company has announced a 60 million share buy back.
I) Rene Quenneville comes to the company as a project manager who was recently employed by Bell and has experience in directing over a thousand employees. Project managers are goal focused facilitators.
J) We have Mario Quenneville as CEO. Prior to coming to SPWP he owned and managed Interlabs which at the time of the merger between SPWP and Interlabs was a wholly owned debt free company valued at several million dollars. Interlabs not only provided a living for Mario and his family but produced sufficient earnings as to be debt free.
K) 65% of the shares are subject to rule 144.
L) With over 100 products in the pipline this company has barely scratched the surface of its impact on the retailers in only one country.
M) IMO the longer this stock is held, the more it will be worth.
L) The company has stated financials are ready and will be released as soon as they are certain they will not adversely impact legal procedings between the company and a former associate of the company. (Probably Walter Davis).
M) The company has stated one of its goals is to become fully reporting and get onto a major exchange.
N) I trust the CEO to look after my best interests as a shareholder as he is the majority shareholder with far more to lose than I do.
O) We have an abundance of bashers. Bashers don't attack bad companies.
P) The company began operations in a 2,000 sq. ft. building. It left that building for a 20,000 sq. ft. building and since then has doubled that to 40,000 sq. ft., plus returned to use the 2,000 sq. ft. as well.
Q) The company has recently added many new employees to handle all the production required.
The bashers would have us believe the company has zero money, few orders and fewer prospects. They would have us believe the company is shovelling shares out the back door to raise capital when in fact they are declining offers of cash. They told us going to the ECRM meeting between vendors and buyers was a "waste of shareholder money". Then they told us being designated vendor status meant absolutely nothing and yet we see the fruits beginning to show. They tell us that the company buying back shares at this point in time is ridiculous, despite the company stating they planne to do so and volume has increased exponentially since that announcement. They tell us money used to buy back shares now would be stupid, but fail to consider those same shares bought for one cent can be private placed in the future for millions of dollars that would provide money needed in the future for further expansion. IMO this company is thinking ahead and I applaud them for it.
As for "waste of shareholder money", can someone tell me how shareholder money can be 'wasted', when not one of us has written a check to the company?
Paul
This is going to be good for HTDS:
"The Oklahoma Judge Denied Shinn Capital Group, Inc. et al.'s Motion for New Trial"
Press Release Source: Hard to Treat Diseases, Inc.
Hard to Treat Diseases, Incorporated Announces Litigation Status
Wednesday December 22, 8:00 am ET
DELRAY BEACH, Fla., Dec. 22, 2004 (PRIMEZONE) -- Hard to Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) Announces Status of Oklahoma (State) and Florida (Federal) Litigation:
On December 10, 2004, The Oklahoma Judge Denied Shinn Capital Group, Inc. et al.'s Motion for New Trial
On November 2, 2004, the District Court of Oklahoma entered an Order dismissing the Second Amended Petition of Shinn Capital Group, Inc. et al. against Hard to Treat Diseases, Inc., a Florida Corporation, allowing Shinn Capital Group, Inc. et al. to proceed in the pending Florida litigation. A copy of the Judge's Order to Dismiss can be viewed on our website at: http://www.htdsotc.com
ADVERTISEMENT
On November 15, 2004, Shinn Capital Group, Inc. et al. filed a Motion for New Trial before the Oklahoma court against Hard to Treat Diseases, Inc., a Florida Corporation seeking to have the court reconsider its ruling dismissing the case.
On December 10, 2004, Judge Carolyn Ricks overruled the Motion for New Trial after considering the briefs, arguments of counsel contained therein, and relevant law.
The Federal Court date for Partial Summary Judgment is set in January 2005.
The Federal Magistrate Judge has ruled that a report and recommendation on whether a preliminary injunction should issue is not in the interests of judicial economy of the Federal Court, because the report and recommendation would most likely be finalized about the same time as the Partial Summary Judgment hearing date. Thus, the court will wait to rule on the preliminary injunction until the Motion for Summary Judgment is ruled upon and the Court considers and rules on Shinn Captial Group, Inc.'s Motion to Dismiss for Lack of Personal Jurisdiction. The Court has already denied Defendant Ronald Shinn and Defendant Gerry Knight's Motions to Dismiss.
We are fully confident in the judiciary and the legal process under which HTTD is proceeding.
HTTD is currently involved in litigation regarding the rights to Tubercin(R). Additional information and details regarding the litigation can be viewed on our website at: http://www.htdsotc.com
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
Contact:
Hard to Treat Diseases, Incorporated
Colm J. King, CEO
(561) 272-6900
www.htdsotc.com
--------------------------------------------------------------------------------
( BW)(NV-ARTEC)(ATKJ) ArTec, Inc., Of Reno, Nevada Announces Completing Its Patent Goals and Has Received the Final Patents from Canada and Western Europe That Were Pending
Pending
Business Editors
RENO, Nev.--(BUSINESS WIRE)--Sept. 27, 2004--ArTec, Inc., (Pink
Sheets: ATKJ) A Pharmaceutical Company announces completing its patent
goals and receiving the final patents from Canada and Western Europe.
On August 13, 2003, the Western European Patent consisting of United
Kingdom, France, Spain, Germany and Italy was issued. On May 11, 2004,
the patent from Canada was issued. The goals accomplished consist of
five final Patents that ArTec, Inc. will utilize:
1. Canada patent issued May 11, 2004, registration number
2,293,821.
2. Western Europe patent issued August 13, 2003, registration
number 0,991,773.
3. United States patent issued August 14, 2001, registration
number 6,274,356.
4. South Korea patent issued October 29, 1998, registration number
173362.
5. Japan patent issued June 12, 1998, registration number
2,790,447.
Dr. Tai Ho Chung, M.D. Ph.D., Principal Partner and Scientific
Advisor for ArTec, Inc. denotes "that having acquired, all five
patents now allows ArTec, Inc. to focus on US FDA submission."
Furthermore, he is encouraged by the fact that research is complete
(Finished Product) and there have been no adverse side effects in
human and mice studies using Tubercin on CANCER. Upon raising funds,
ArTec, Inc. will move quickly into US FDA submission.
What is Tubercin?
The United States Patent issued August 14, 2001, states in the
abstract summary the following:
"A carbohydrate complex, which is a mixture of low
molecular-weight polysaccharides of an arabinomannan structure
extracted from Mycobacterium tuberculosis, is highly effective in
treating various cancer patients without incurring any adverse side
effects." For further information, the US Patent and Trademark
Offices's Official web site can be retrieved from ArTec, Inc.'s web
site at www.artec-inc.net.
Forward-looking statements in this press release, the company
cautions the investors, involve risks and uncertainties pursuant to
the "Safe Harbor" provisions of the Private Securities Litigation
Reform Act of 1995. In addition, the company cautions investors that
it undertakes no obligations or responsibilities to publicly update
these forward-looking statements to reflect Company's expectations
with regard to these forward-looking statements or the occurrence of
unanticipated events.
ArTec, Inc. A Pharmaceutical Company whose goal is to improve the
quality of life!
--30--TM1/na*
CONTACT: ArTec, Inc.
Gerry Knight, 800-388-8875
gknight@artec-inc.net
www.artec-inc.net
KEYWORD: NEVADA ITALY SPAIN GERMANY FRANCE UNITED KINGDOM
INTERNATIONAL CANADA EUROPE
INDUSTRY KEYWORD: PHARMACEUTICAL PRODUCT
SOURCE: ArTec, Inc.
ArTec completes phase Ib Tubercin protocol
ArTec Inc has reported that an FDA specialist hired by the company has completed the protocol for the FDA phase Ib human study designed to evaluate the efficacy and safety of anticancer treatment Tubercin in melanoma patients.
ArTec Inc has reported that an FDA specialist hired by the company has completed the protocol for the FDA phase Ib human study designed to evaluate the efficacy and safety of anticancer treatment Tubercin in melanoma patients.
This study is directed toward adult subjects who are suffering from metastatic stage IV melanoma who cannot be treated by surgery, and will include approximately 30 people between the ages of 18 and 65.
The study, designed to be conducted over a 42-day period, will evaluate the administration of Tubercin alone, as well as in conjunction with other established immunotherapy treatments such as interleukin, alpha interferon and granulocyte stimulating macrophage-colony stimulating factor.
The results of the study will be evaluated and measured for decreases in mass of tumors, improved clinical signs in patients and relief of pain. ArTec's management intends to submit the study to an institutional review board of the FDA for the approval.
"The completion of this carefully crafted protocol is the most significant step we have taken toward the process of gaining US FDA approval for our revolutionary compound," noted Dr Chung, scientific advisor of ArTec and inventor of Tubercin.
"Tubercin in the past has been used only on a compassionate care basis outside the US. It is important that we be proactive in moving our agenda forward to broaden the availability of this compound to suffering people in the US."
ArTec is currently seeking an executive director from a leading oncology research institute that will oversee this phase Ib study. The company anticipates that the approval process will take several weeks, after which it intends to conduct the study at a prominent cancer hospital in the US.
Datamonitor Europe
Charles House
108-110 Finchley Road
London
NW3 5JJ
United Kingdom
t: +44 20 7675 7000
f: +44 20 7675 7500
e: euroinfo@datamonitor.com
Datamonitor Germany
Kastor & Pollux
Platz der Einheit 1
60327 Frankfurt
Deutschland
t: +49 69 97503 119
f: +49 69 97503 320
e: deinfo@datamonitor.com
Datamonitor America
245 Fifth Avenue
4th Floor
New York
NY 10016
United States of America
t: +1 212 686 7400
f: +1 212 686 2626
e: usinfo@datamonitor.com
Datamonitor Asia-Pacific
Darling Park
Tower 2, Level 21
201 Sussex Street
Sydney
NSW 2000
Australia
t: +61 2 9006 1526
f: +61 2 9006 1559
e: apinfo@datamonitor.com
Datamonitor Japan
Wakamatsu Bldg 7F
3-3-6 Nihonbashi-Honcho
Chuo-ku
Tokyo 103-0023
Japan
t: +81 3 6202 7681
f: +81 3 4512 8117
e: jpinfo@datamonitor.com
HTDS -- Hard to Treat Diseases, Inc.
Com (1 Cent)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Hard to Treat Diseases, Incorporated Files U.S. Provisional Patent Application
DELRAY BEACH, Fla., Dec 17, 2004 (BUSINESS WIRE) -- Hard to Treat Diseases, Incorporated (HTTD) (Pink Sheets: HTDS) Announces Filing of U.S. Provisional Application for Methods and Compositions for Treatment of Viral Infections.
HTTD is no longer a "one-drug company" that is reliant solely on the promotion of Tubercin(R).
The provisional application discloses the testing results of HTTD's proprietary formulation for the treatment of viral infections, which was recently filed on behalf of HTTD as a result of ongoing testing and research conducted on various compounds and substances that HTTD owns, controls or has the licensed rights to. Testing results could not be released until the provisional application was filed due to the confidential and sensitive nature of the information. Recently, the major focus of HTTD, its research team and patent attorneys has been on preparing and filing the provisional application.
Testing results to date have been finalized and incorporated in the provisional application. An overview of the results will be released in the very near future. The testing documents comprise a valuable asset that has been created for HTTD. This asset, along with the underlying testing documents, is confidential, not available to competitors, and HTTD has taken extraordinary steps to maintain its confidential nature and contents.
HTTD is no longer a "one-drug company" that is reliant solely on the promotion of Tubercin(R). In addition to our proprietary formulation and various compounds, referenced in the provisional application, HTTD also acquired and holds the worldwide (except Korea) marketing rights and license to manufacture, use, market, distribute and otherwise to commercialize Tubercin(R), which includes Tubercin(R)'s issued patents in the following countries:
Japanese patent: issued 6/12/98
United States patent: issued 8/14/01
European patent: issued 8/13/03
Canada patent: issued 5/11/04
Mr. Colm J. King, CEO of HTTD, commented, "HTTD's value and goals have been strengthened with the provisional application. We will continue to aggressively advance the testing of Tubercin(R) in the U.S.; in addition to aggressively advance the testing of our proprietary formulation and other compounds and substances, contained in the provisional application, in the U.S.; and make strategic decisions with the goal of being involved in negotiations with major drug firms within 18 months."
Mr. King added, "Testing and evaluation results are an essential interim step in obtaining the FDA approval necessary to market a product. Our testing and research has been supervised and conducted in U.S. FDA approved laboratories by experienced medical and scientific professionals. HTTD will vigorously enforce its lawful rights, which includes defending its advantageous business relationships and negotiations that are instrumental in establishing a solid reputation and significant presence in our field and attaining the goals of benefiting patients and HTTD's shareholders."
HTTD is currently involved in litigation regarding the rights to Tubercin(R). Additional information and details regarding the litigation can be viewed on our website at: http://www.htdsotc.com
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
SOURCE: Hard to Treat Diseases, Incorporated
Sorry my friend, just following board rules (rule #4).
I hope you can understand.
Guide for Stock-Specific and Free Zone Board Moderators
(These boards can be posted on by any registered free or paid member of the site.)
Note: When managing one of these boards, you have six reasons to choose from when deciding whether or not a post should be removed:
1) Duplicate – an accidental duplicate post by a member.
2) Personal Attack – when someone attacks a person, with name calling, or relating to the messenger and not the message.
3) Spam – a message that is being posted promoting other sites, stock-related or not, that has no use in the discussion (for example, if your board is about Ford Motors, a link promoting amazing returns running a home-based business is worthless to the discussion).
4) Vulgarity – cursing of any kind unacceptable on your board.
5) Violation of Privacy – posting of any personal identifiable information (email, real name, phone, address, etc)
6)Threat – someone threatening another member in some fashion
BuzzOnDaBeach, We DO NOT tolerate this language on this board, "(now I'm a f**king nail expert :0)"
MarriedwithChildren, try these
1-727-531-4157
1-727-542-0700
December 15, 2004 08:00 AM US Eastern Timezone
ArTec, Inc. Completes Protocol for Phase I b Study of Tubercin
RENO, Nev.--(BUSINESS WIRE)--Dec. 15, 2004--ArTec, Inc. (Pink Sheets:ATKJ) announced today that Nancy Angus, an FDA specialist hired by ArTec, Inc., has completed the protocol for the FDA Phase I (b) Human Study designed to evaluate the efficacy and safety of Tubercin in certain cancer patients. This study is directed toward adult subjects who are suffering from metastatic Stage IV melanoma who cannot be treated by surgery, and will include approximately 30 people between the ages of 18 and 65. The study, designed to be conducted over a 42-day period, will evaluate the administration of Tubercin alone, as well as in conjunction with other established Immunotherapy treatments such as Interleukin, Alpha Interferon and Granulocyte Stimulating Macrophage-Colony Stimulating Factor. The results of the study will be evaluated and measured for decreases in mass of tumors, improved clinical signs in patients and relief of pain. Management intends to submit the study to an Institutional Review Board of the FDA for the approval.
Dr. Chung, scientific advisor of ArTec and inventor of Tubercin noted, "The completion of this carefully crafted protocol is the most significant step we have taken toward the process of gaining United States FDA approval for our revolutionary compound." He further added, "Tubercin in the past has been used only on a compassionate care basis outside the U.S. It is important that we be proactive in moving our agenda forward to broaden the availability of this compound to suffering people in the U.S. We must create an image of wellness for cancer victims that Tubercin is a viable option to consider."
ArTec is seeking an executive director from a leading oncology research institute that will oversee this Phase 1 (b) study. Management anticipates that the approval process will take several weeks, after which it intends to conduct the study at a prominent cancer hospital in the United States.
Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated
http://www.duanereade.com
Now they even show how many in a box
I would be careful with SHRN, GOOGLE has FROOGLE and is very similiar. I have used FROOGLE in the begining and it is getting better and better eveyday.
Look at HTDS chart analysis:
http://quotes.barchart.com/texadv.asp?sym=htds
HERE WE GOOOOOOOOOOOOOO
Press Release Source: Superwipes, Inc.
Superwipes in Additional Stores
Monday December 6, 7:30 am ET
CLEARWATER, FL--(MARKET WIRE)--Dec 6, 2004 -- Superwipes, Inc. (Other OTC:SPWP.PK - News) has released a list of 65 stores carrying Superwipes products through a private label arrangement with Barielle.
"Our shareholders are invited to visit these establishments to view our products in-store," said Mario Quenneville, President and CEO of SPWP. "Barielle continues to be an excellent ambassador of Superwipes."
About Face Ltd. Barielle Sales International
Barrington Court Health/Beauty Bartell Drug
Bath & BodyWorks The Beauty Lounge
Beauty Solutions Bel Air Beauty Center
Bellas Beauty Supply Beverly Hills Beauty Center
Bigelow Brent-Air Pharmacy
Bruce Smith Drugs Buff Spa
Buff Spa at Bergdorf Goodman Burton's Pharmacy
Bushard's Pharmacy California Pharmacy
Carl's Pharmacy Chateau Drug
Clarkson Sq Pharmacy Clyde Chemists
Colonial Drug Concord Chemists
Cosmetique of Vero Beach Dana Drug
Dan's Beauty Supply Direct Connections
Douglas Cosmetics - NJ Gables Beauty Supply
Gessler Drug Image Beauty
Jet Beauty Supplies Kamay Beauty Center, Palm Desert
Kamay Beauty Center, Oceanside, CA Kamay Beauty Center, Solano Beach
Kamay Corporate Key Pharmacy
King's Peachtree Battle Drugs Kristy (Beverly Blvd.)
L'Shear Hair Design La Femme Perfumery
La Peer Beauty Ladue Pharmacy
Liss Pharmacy Mendham Apothecary
New London Pharmacy Number One Beauty
Pasteur Pharmacy Ricky's Store - SOHO
Ricky's Urbangrove Schimerlik, Martin
Schiller's Pharmacy Sephora
Sephora.com South Shore Beauty Center
Suburban Pharmacy Super Care Drugs
Sundaez Salon Tower Chemists
Town & Country Pharmacy Westside/Vicenti Pharmacy
Whisper White's Pharmacy
Zitomer's Pharmacy
Superwipes, Inc. products can be found in leading food, drug, convenience and beauty supply stores across North America and Europe such as ULTA, Sephora, Duane Reade, and Dillards, etc. Superwipes are formulated with organic materials that are safe for the environment and perform with an efficacy equal to or exceeding the toxic chemicals they replace.
Superwipes, Inc. conceives, designs and formulates unique cosmetic and all-purpose products from organic materials with a variety of applications including fingernail polish remover, make up remover, sneaker cleaner wipes, instant shoe shine wipes, acne treatment wipes, eye glass, cleaner and defogger, car interior leather cleaning pads, vitamin E applicators, etc. Superwipes' products are sold in leading food, drug, convenience and beauty supply stores throughout North America and Europe. More Superwipes' products are in various stages of development, and should be released throughout 2004. Please visit www.superwipes.com
This release contains forward-looking information within the meaning of The Private Securities Litigation Act of 1995. Forward-looking statements may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," "should" or "might" occur. Such forward-looking statements involve certain risks and uncertainties. The actual results may differ materially from such forward-looking statements. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results (expressed or implied) will not be realized.
Contact:
CONTACT:
Superwipes, Inc. / Taylor Capital Inc.
Stephen Taylor
(973) 351-3868
stephtayl9@aol.com
http://www.superwipes.com
--------------------------------------------------------------------------------
Source: Superwipes, Inc.
Sorry guys & girls, if one plays by the rules then he or she can post.
1) Duplicate – an accidental duplicate post by a member
2) Personal Attack – when someone attacks a person, with name calling, or relating to the messenger and not the message.
3) Spam – a message that is being posted promoting other sites, stock-related or not, that has no use in the discussion (for example, if your board is about Ford Motors, a link promoting amazing returns running a home-based business is worthless to the discussion).
3) Vulgarity – cursing of any kind unacceptable on your board
4) Violation of Privacy – posting of any personal identifiable information (email, real name, phone, address, etc)
5) Threat – someone threatening another member in some fashion
If it doesn’t fit into either of those categories, it should not be removed.
I will do my best to monitor this board daily.
TO educate all (who is this referring to):
Lesson 1: Remember, BASHERS NEVER Bash A BAD STOCK. Check the boards for stocks with no potential. They never have any Bashers. Bashers only go after stocks that are moving up or have excellent potential to do so. Bashers work to bring the price down to either increase their position at the expense of others or help a Short make their bones.
Lesson 2: BASHERS ALWAYS BRING UP OLD NEWS THAT YOU HAVE HEARD MANY TIMES. New startup companies always have a few bits of bad news. The Basher will post this over and over again. Unsophisticated Bashers will try to freshen up old news with a new date or by-line in an attempt to fool you.
Lesson 3: BASHERS POST MANY TIMES A DAY. They try to wear you out. They comment on everything, every other post, and can answer every question. THEY KNOW IT ALL! There is no positive comment they won't Bash. They try to control the board. True longs may have to confront the Bashers or they will appear to the newbies as being the people with all the information. This is best accomplished by posting positive, well researched data on the company, repetitively, while trying hard not to engage the Bashers in direct repartee. REMEMBER - LONGS... RESIST USING THE BASHERS ALIAS!
Lesson 4: BASHERS WILL LIE TO YOUR FACE. Never trust a Basher. The truth on startup companies is that they make mistakes. What new company hasn't? The Basher will compare your issue to a another companies, financials - deals - management, etc., trying to lure you into making an Apples to Oranges comparison. Remember each company is unique and while it is prudent to seek out established indicators, do so with care and don't take someone else's word for it. Strive to come up with at least a "six-pack" of indicators so your vision of the state of a company is not tied to a single barometer. Not doing so is tantamount to going to a Race Track and betting on the "Pretty Brown Horsey". BASHERS WANT TO WHISPER IN YOUR EAR - PLANT A SEED OF DOUBT, AND HOPE THAT YOU ARE NOT SAVVY ENOUGH TO RESEARCH THE TRUTH ON YOUR OWN. This is how they achieve their greatest success.
DOUBT + FEAR + LAZINESS = BAIL OUT!
This is your investment... work for it, protect it and don't panic on the words of very shadowy figure that "has your best interest in their heart". Consider that one factor: Someone you have never met, is not a member of your family, is now, out of the goodness of their hearts - GIVING YOU FREE ADVICE (that you didn't ask for). It's a no brainer. They have motives $$$$$$$$$$$$.
Lesson 5: Bashers know YOU CAN'T VERIFY THEIR STATEMENTS. That's why they make the vague statements they do. They rely on you being to lazy to research their droppings other than to scan the board for others opinions. This is particularly dangerous when you consider that Bashers work in packs and often validate and back up each others nonsense with what appears to be "innocuous and unsolicited" verification by comrade Bashers. Let's face it, we are all conditioned to "believe" everything we see in writing. If others by virtue of their "posts" also confirm this belief, then we are subconsciously doomed to swallow the hook, line and sinker... Basher - 1 Honest Investor - 0
Lesson 6: The Bashers PLAY ON YOUR LACK OF KNOWLEDGE. They can lie about information and you won't know the difference (unless you have done your own DD on the company and know the truth and facts).
Lesson 7: Bashers play on your lack of patience. You have held a stock for a while. You knew it will be a big stock someday, but the BASHER CAN GET TO YOU BECAUSE YOU ARE TIRED OF WAITING FOR YOUR GAIN. That's when the Basher is best. You are tired. You have forgotten the goal for the stock was to hold it for one year. The Basher is bothersome, so you dump it on a bad day. Some others also dump. Then you get mad for your loss and return to let everyone know how mad you are. Then you turn into a semi-Basher as well. THE BASHER HAS WON, AND GAINED A NEW ALLY - YOU!
Lesson 8: BRING THE PRICE DOWN. That is the Basher's job. The truth is not important. Lies are the norm. Post continuously on the board every day. They are trying to scare the newbies that are just investigating a stock. They are trying to wear down the faithful longs on the board and gain free reign and control.
A BASHER HANDBOOK:
Do not underestimate a Bashers influence on a stock. The Pro's are good at what they do and what they do is profit from your losses. Below is their "hand-book". Learn from it or you will be donating your hard earned money to them!
Lets see:
1) Mario was sick awhile.
2) Four hurricans hit Florida.
3) No cents (pun) in reporting numbers until business is up and turning a faily good profit.
4) Lawsuit with scumbag Walter Davis for almost 2 years. imo
I am still long and accumulating. Already made $ when stock went to .09 and .04.
As for bashers on boards, their words are a waste of keystrokes.
This is a penny stock which I have made dollars.
HAppy Holidays Everyone.
Wall Street News Alert: Hot Stock Highlights! November 30, 2004
Weston, FLA., Nov 30, 2004 (M2 PRESSWIRE via COMTEX) -- Wall Street News Alert`s "stocks to watch" this morning are: Diamant Art Corp. (OTCBB: ARIOF), Technology Visions Group, Inc. (OTCBB: TVGR), Sprint Corp (NYSE: FON), The Walt Disney Company (NYSE: DIS) and Superwipes Inc (OTC: SPWP).
SPWP
Time & Sales
Price Size Time
0.01 100000 15:46:15
0.01 50000 15:29:29
0.01 60000 15:21:16
↓ 0.01 65000 14:39:01
↑ 0.012 27187 14:36:28
0.01 20000 14:25:04
0.01 10000 14:24:44
↓ 0.01 25000 14:24:20
↑ 0.011 100000 14:24:10
↓ 0.01 40000 14:23:48
0.011 5000 14:23:12
↓ 0.011 5000 14:23:09
↓ 0.012 5000 14:22:39
0.013 25000 14:20:00
↑ 0.013 185299 14:16:43
↓ 0.012 100000 14:16:41
↑ 0.013 16127 14:14:23
↓ 0.012 200000 13:56:37
↑ 0.013 95000 13:56:31
↑ 0.012 5000 13:43:48
↓ 0.011 50000 13:43:35
0.012 135000 13:42:48
0.012 40000 13:41:49
↑ 0.012 155000 13:35:14
↑ 0.011 20000 13:34:56
↓ 0.01 50000 13:31:59
0.011 2000 13:19:34
0.011 2000 13:06:12
↑ 0.011 2000 13:05:18
0.009 75000 13:02:25
By: rbillardny
28 Nov 2004, 07:42 PM EST
Msg. 8610 of 8612
Jump to msg. #
Just bought a box of Superwipes at my local Duane Reade.
I have been a shareholder and reader of this board for over
a year, but think this is my first post.
This afternoon, I was in a local (Long Island, NY) D-R store
and found a floor standing display of Superwipe Nail Polish
Remover, NOT under the Barielle name. This is the box that
appears on the Superwipe web page. The display was full,
mine might have been the first sale. Don't know how long they
have been there.
Receipt reads: SUPERWIPES NL PLSH 1T (one item) 2.99
So they ARE out in the stores, and in time for Christmas!
Bob
By: salvarai
28 Nov 2004, 04:55 PM EST
Msg. 2970 of 2971
Jump to msg. #
I am not sure the market has realized the importance of the dismissed case in Oklahoma. Basically, Shinn and Knight have NO case pending in any court at the moment against HTDS/HTTD. The injunction pending is against Shinn for criminal actions, and the Federal case in January is again against Shinn and seeks to confirm that all rights to Tubercin, except in Korea, are solely HTDS's property. As stated in the last news release, Shinn has filed claims against HTTD, but HTTD filed a motion to dismiss the claims. Based on the Oklaoma dismissal, strong chances are that Shinn's claims will again be dismissed. We are patiently awaiting the court's decision anytime now.
In my opinion, there is a strong possibility that SHinn will be denied any right to shares from the agreement, as his criminal actions simply cannot be rewarded by the court.
Now with HTTD's case recognition by the court imminent, and positive clinical results to be released in two weeks time at most, we are looking at extremely exciting times for shareholders.
Hey J, old news but,
Here is alittle info:
All members of Walter Davis’ Group expressly resign all offices and directorships held in SMNC and its subsidiaries. The Davis Group withdraws opposition to the pending Motion to Dismiss the proceeding for relief under Chapter 11 of the Bankruptcy Code, and its motion for confirmation of the proposed Chapter XI plan.
Additionally, Walter Davis shall surrender and release a $90,000 promissory note, payable to his order and executed by him for SMNC and signed by Mr. Quenneville for Interlabs.
We are still trying to find out how many shares this clown actually owns.
I will keep you posted by the boards.
The way I see it.
By: salvarai
18 Nov 2004, 11:05 PM EST
Msg. 2942 of 2943
Jump to msg. #
Luchesse, interesting post with a good balance of optimism and realism. I would like to point out in return where we seem to diverge slightly, and it's mainly regarding the timeline of events.
Firstly, I believe news about the injunction on Artec are going to come before the end of this month, i.e. in two weeks time at most. If granted, this injunction will likely secure the court's decision at the federal court in January, and investor will react to the injunction very positively.
Secondly, I also believe HTDS would already be in a position to announces very positive clinical results, but is waiting for the injunction to be granted. That way, the clinical results won't be shadowed by any serious threat of patent rights removal, etc.
Thirdly, I am not sure if I correctly interpret your statement in that regard, but current clinical testings are done on human cells, not mice (as the toxicity tests from last fall were indeed). Which means that whatever the results are going to show, it is the true effect of Tubercin on human cells.
Fourthly, referring back to a conversation I had with Dr Shapiro last May, he clearly stated that in case Tubercin actually showed very clear and significant results on one or several diseases, their institute had the federal recognition that would allow a fast track FDA approval: it can be as short as 3-6 months if justified.
Fifthly, C.King's objective is not to go through all 3 phases of FDA approval testing: he clearly stated in news releases, and repeated to me in conversations, that once results are out, there will be pharmaceutical companies interested in taking over Tubercin to the next level. Meaning: Buy out.
So for all these reasons (and others...) I believe that we are already entering the stretch home here. As soon as injunction/court cases are cleared and positive clinical results are out, we should expect significant changes in the share value of HTDS. And not long term. I myself, believe Christmas is going already to be very nice this year.
Hey 2nd Mil,
Lets agree to a out of court settelment of $5.00 a share
SOON:
By: salvarai
17 Nov 2004, 07:11 PM EST
Msg. 2933 of 2938
Jump to msg. #
Tube, I discussed with King on that very issue. If HTDS's injunction is granted, it should include a restriction on any share that Shinn would be allowed to have back. Now I say allowed because it is not even clear that the court will grant Shinn any share whatsoever. There are indeed a number of reasons not to: the fact he has given the shares back to HTDS ii) the fact that he has stolen money ($200,000) from HTDS's bank account; the fact that he has used that money to hurt HTDS's shareholder's interest in making publicly (through ATKJ) false claims regarding the legal holder of patent rights; etc.
In addition to reimbursing the stolen money, HTDS is seeking punitive damage from Shinn for is criminal actions, including cancellation of those shares. Even if Shinn gets to keep some shares (or all), a restriction on those shares will be requested, and typically in these cases, granted. In other words, Shinn will not be able to affect HTDS's trading through those shares before the company will have secure clinical testing and very likely, a deal with a pharmaceutical company.
By: salvarai
18 Nov 2004, 03:11 AM EST
Msg. 2936 of 2938
Jump to msg. #
Tube, I forgot to mention in my last post that all that information (Shinn steeling money, HTDS requests regarding Shinn present and future role w.r.t. HTDS) is also included in the court injunction by HTDS, that you can review on their Website.
By: salvarai
18 Nov 2004, 11:38 AM EST
Msg. 2938 of 2938
(This msg. is a reply to 2937 by tube15.)
Jump to msg. #
Tube, as far as I recall, at the time of their resignation, they included in their letter that their share certificates were left with the company and thereby, they were "breaking the deal". Shinn apparently thought he could just cancel the contract he had duly signed 5 months prior with HTDS at his will, without consideration for shareholders, SEC regulations or american contractual laws.
But, as we know from personal and business experience, one cannot simply cancel a contract! The injunction should reenforce the contract that Shinn duly signed and recognize HTDS all patents rights for Tubercin. As I mention in my previous posts, as for Shinn's shares: the court may decide to restrict those shares for a period of time, or even cancel these shares as punitive damage for Shinn's criminal actions with the company.
Let me share with you an interesting information: Shinn's first lawyer has resigned, and HTDS has already refused an out of court agreement with Shinn's second lawyer. Shinn may start to understand he is in trouble, and HTDS has all intention to make sure that Shinn will not be in a position to affect HTDS in any way whatsoever.
By the way: good choice no to listen to 102579. I have put him on ignore myself for a long time, and I don't miss him a bit.
By: nformd
16 Nov 2004, 02:44 PM EST
Msg. 8460 of 8467
(This msg. is a reply to 8443 by cap_up.)
Jump to msg. #
I visited Superwipes last week and everything is growing and getting larger.
Mario told me that he was taking delivery of retail displays and will be taking delivery of $250,000 worth of materials for making the superwipes.
The Duane Reade stocking order has been delivered and working on getting the CVS order moving. Each store was delivered 3 cases (different fragrances) of 100 boxes (300 total) of wipes and will be a stand-alone display not requiring shelf space.
The expanded offices are taking shape and loking great. They currently have around 15,000 boxes in inventory.
NF
November 15, 2004 05:54 PM US Eastern Timezone
Cancer Treatment Results from Tubercin reported by ArTec, Inc.
RENO, Nev.--(BUSINESS WIRE)--Nov. 15, 2004--ArTec, Inc., (Pink Sheets:ATKJ) announced that Dr. Tai Ho Chung, formulator of Tubercin and the Company's scientific advisor, along with members of a research team from Kyungpook National University Hospital, Daegu, South Korea, recently reported the successful results on the long term treatment of a 26 year old breast cancer patient. Although already in an advanced stage of the disease, the subject after a treatment protocol that combined Tubercin with conventional radiation has been in remission for the past three years through November 2004. Treatment with Tubercin commenced in the year 2000, primarily because the patient had not responded well to conventional therapies. Three years after the initial treatment, remarkably, the patient remains in remission.
Dr. Chung noted that, "This particular case demonstrates clinically that Tubercin is effective, as an adjuvant to radiation, and can be successfully combined with conventional cancer treatments without the fear of adverse side-effects." He further commented, "There are other cases where Tubercin has been successful with breast cancer as well as other cancers when administered as the only treatment."
Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
Contacts
ArTec, Inc., Reno
Gerry Knight, 800-388-8875
www.artec-inc.net